BioPharma Resources

Drugs by condition

Drugs approved for gout

Brand-name prescription drugs and biologics whose FDA label lists gout as an approved use. Matched on the label phrases: "gout", "hyperuricemia".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

11

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

4

New molecular entities and new biologics

In development

15

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for gout.

  • Gloperba (Colchicine) · Scilex Pharms Jan 30, 2019
  • Mitigare (Colchicine) · Hikma Sep 26, 2014
  • Krystexxa (Pegloticase) · Horizon Pharma NovelPriority reviewOrphanSep 14, 2010
  • Ilaris (Canakinumab) · Novartis Pharms NovelBreakthrough therapyPriority reviewOrphanJun 17, 2009
  • Uloric (Febuxostat) · Takeda Pharms USA NovelFeb 13, 2009

All approved drugs for gout, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 61 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Xanthine Oxidase Inhibitor (4)

  • Uloric Febuxostat · Takeda Pharms USA · 2009
  • Zyloprim Allopurinol · Casper Pharma LLC · 1966
  • Allopurinol Allopurinol · Watson Labs · 1984
  • Allopurinol Allopurinol · Watson Labs · 1984

Alkaloid (2)

  • Gloperba Colchicine · Scilex Pharms · 2019
  • Mitigare Colchicine · Hikma · 2014

Nonsteroidal Anti-inflammatory Drug (2)

Uric Acid-specific Enzyme (1)

  • Krystexxa Pegloticase · Horizon Pharma · 2010

Class not listed in FDA's data (2)

  • Ilaris Canakinumab · Novartis Pharms · 2009
  • Naprelan Naproxen Sodium · Twi Pharms · 1996

Drugs in development for gout

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • EtoricoxibPhase 34 trials

    Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain

  • AR882Phase 33 trials

    Arthrosi Therapeutics · Gout, Hyperuricemia, Gout Chronic

  • DotinuradPhase 33 trials

    Crystalys Therapeutics · Gout, Tophaceous Gout

  • HRS-2129Phase 33 trials

    Shandong Suncadia Medicine Co., Ltd. · Acute Gouty Arthritis, Postoperative Analgesia, Postoperative Pain in Orthopaedics

  • PlonmarlimabPhase 33 trials

    TJ Biopharma Co., Ltd. · Acute Gouty Arthritis, Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytoses

  • TigulixostatIBI128, LC350189Phase 33 trials

    Innovent Biologics Technology Limited (Shanghai R&D Center) · Gout, Hyperuricemia, Gout Flare

  • ABP-671Phase 32 trials

    Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout

  • ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease

  • Etoricoxib fixed doseEtoriPhase 32 trials

    Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain

  • HR091506Phase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Gout With Hyperuricemia in Adults

  • ABP-745Phase 22 trials

    Atom Therapeutics Co., Ltd · Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management

  • BR2251Phase 21 trial

    BioRay Pharmaceutical Co., Ltd. · Gout and Hyperuricemia

  • IG3018Phase 21 trial

    Intelligem Therapeutics Australia Pty Ltd. · Hyperuricemia, Hypouricemia, Renal

  • PRX-115Phase 21 trial

    Protalix · Gout

  • SSGJ-613Phase 21 trial

    Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Gout Arthritis

1 discontinued brand-name drugs whose label still names it

More on gout: recruiting trials · published research

Related in immunology and inflammation: Rheumatoid arthritis · Plaque psoriasis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Ankylosing spondylitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.